Treating wet AMD with radiation


A single procedure may be as effective as repeated anti-VEGF injections claims Timothy L. Jackson.

Key Points

Choroidal neovascularization (CNV) is a result of over-expression of vascular endothelial growth factor, recruitment of inflammatory cells, and fibroblasts. Radiation is known preferentially to damage proliferating endothelial cells. Epimacular brachytherapy is an AMD therapy that utilizes a novel surgical device to deliver targeted beta radiation to active AMD lesions. Unlike anti-VEGF agents, radiation is thought to eliminate CNV vessels permanently, rather than simply suppress them. For this reason, the device offers the prospect of a one-off operation, rather than a lifetime of intravitreal injections entailing considerable expense, patient inconvenience, and a small but cumulative risk of complications.

Early studies of radiation

Successive attempts to provide a more focal delivery under the retina had only limited success, as the very process of accessing the subretinal space caused damage. By contrast, epimacular brachytherapy - which involves the delivery of beta radiation via a vitrectomy procedure - has the potential to provide a highly targeted delivery of beta radiation without surgical damage to the retina.

Details of the procedure

The device consists of a hand piece with a 20-gauge cannula, within which resides a retractable radiation source (the radioactive isotope strontium-90).

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Colman Cawe, director of fundraising and communications, Orbis UK
Related Content
© 2023 MJH Life Sciences

All rights reserved.